Skip to content
BillHelp
Menu
YOUR BILLHELP GUIDE

PET Scan Denied by Insurance

What can I do if insurance denies a PET scan?

A plan can deny a PET scan because an approval was missing, because it says the scan is not medically necessary, or because of the facility or the records. HealthCare.gov says preauthorization is a decision that a service is medically necessary, not a promise the plan will pay. For Original Medicare, national coverage determination 220.6.17 sets different FDG PET rules for the first anti-tumor treatment strategy and for later scans. A Medicare Advantage plan has to follow that national coverage determination. This page explains the denial and the appeal. It does not promise that the scan will be covered.

Get help with my bill →
General U.S. guidance. Your plan documents and denial notice explain the process that applies to your case. Medicare, Medicaid, and other programs may use different rules. This is not medical or legal advice, and no result is guaranteed.

What should I read on a PET scan denial?

Read the denial for the type of PET, the date, the body area, and the reason. A missing approval, a medical-necessity decision, and a mismatch of facility or date are different problems. HealthCare.gov says a plan may require preauthorization before a service, except in an emergency, and that preauthorization is not a promise of payment. If the notice names a company that reviewed the scan for the plan, or calls that company a radiology benefit manager, the appeal is still the one on the plan's notice. That company is not a separate appeal system. If the notice says approval was missing, see a prior authorization denial. If it says the scan is not medically necessary, see a medical necessity denial.

An MRI denial and a CT denial are different scans, even when a PET is done on a combined machine. See an MRI denial and a CT scan denial. If the PET was ordered to plan cancer treatment, the treatment denial is in a cancer treatment denial. A bill from the radiologist, when you did not meet that physician, is in a bill from a doctor you never saw.

References: HealthCare.gov: Preauthorization · HealthCare.gov: Internal appeals

Does Original Medicare cover an FDG PET for cancer?

National coverage determination 220.6.17 is the Medicare policy for FDG PET for oncologic conditions. FDG is the injected radiopharmaceutical 2-[F18] fluoro-2-deoxy-D-glucose. Effective for claims with dates of service on and after June 11, 2013, CMS ended the coverage-with-evidence-development requirement, including the National Oncologic PET Registry, for the oncologic FDG uses in this section. The NCD says that decision does not change coverage for PET that uses NaF-18, ammonia N-13, or rubidium-82. If the denial names a different tracer or a different section of NCD 220.6, use that section. This page does not restate those other sections.

For the initial anti-tumor treatment strategy, the NCD says CMS nationally covers one FDG PET study for a person who has cancer that is biopsy proven or strongly suspected based on other diagnostic testing, when the treating physician determines that the study is needed to determine the location or extent of the tumor for one of three purposes: to decide whether the person is an appropriate candidate for an invasive diagnostic or therapeutic procedure; to determine the optimal anatomic location for an invasive procedure; or to determine the anatomic extent of the tumor when the recommended treatment reasonably depends on that extent. The NCD says this initial strategy is what used to be called diagnosis and staging. The same NCD's revision history says that, effective August 4, 2010, CMS removed an absolute limit of only one FDG PET for the initial strategy and left any additional FDG PET for that initial strategy to the local Medicare contractor. For the subsequent anti-tumor treatment strategy, which the NCD says used to be called restaging and monitoring response to treatment, the NCD says three FDG PET scans are nationally covered when used to guide later management after initial anticancer therapy is completed. Coverage of more than three FDG PET scans for that later strategy is determined by the local Medicare Administrative Contractor.

Medicare.gov groups a PET scan with an MRI, a CT scan, an X-ray, and other diagnostic non-laboratory tests. Part B covers the test when your provider orders it to find or treat a medical problem. The coinsurance on that page, and the accreditation rule for a test outside a hospital, are stated in a CT scan denial. This page does not restate them. 42 CFR 422.101(b)(1) requires a Medicare Advantage organization to comply with CMS national coverage determinations, including this NCD where it sets the coverage rule. The plan's appeal is in how to appeal a Medicare Advantage denial.

References: CMS NCD 220.6.17: FDG PET for oncologic conditions · Medicare.gov: Diagnostic non-laboratory tests, including MRI · 42 CFR 422.101: Medicare Advantage basic benefits, including traditional Medicare coverage criteria

Which initial FDG PET uses does Medicare not cover?

The NCD's chart marks both the initial strategy and the subsequent strategy as covered for the cancers it lists, except the initial-strategy limits below. Subsequent strategy is marked covered for every cancer on the chart, including prostate, and the three-scan national limit still applies. The chart also marks all other solid tumors, myeloma, and all other cancers not listed as covered for both strategies.

The NCD continues to nationally cover an initial FDG PET for male and female breast cancer only when it is used in staging distant metastasis. It nationally non-covers FDG PET for the diagnosis of breast cancer and for the initial staging of axillary nodes. It nationally covers an initial FDG PET for melanoma other than for the evaluation of regional lymph nodes, and it nationally non-covers that regional-node evaluation. It nationally covers FDG PET for the detection of pre-treatment metastasis, meaning staging, in newly diagnosed cervical cancer following conventional imaging. It nationally non-covers FDG PET for the diagnosis of cervical cancer related to the initial strategy. It nationally non-covers the initial anti-tumor treatment strategy for adenocarcinoma of the prostate. Read the denial for the cancer and for whether the plan called the scan initial or subsequent. Do not ask anyone to relabel a later scan as the initial study, or to describe a non-covered use as a covered one.

References: CMS NCD 220.6.17: FDG PET for oncologic conditions

What should I ask the ordering doctor for?

Ask the ordering physician, in writing, for the determination the NCD describes when the denial is an Original Medicare or Medicare Advantage FDG PET for cancer. That is whether the cancer is biopsy proven or strongly suspected, whether this scan is for the initial strategy or a later one, which of the three initial purposes applies if it is the first strategy, and how many subsequent FDG PET scans have already been done for this cancer diagnosis. For newly diagnosed cervical cancer, the NCD's covered staging use follows conventional imaging, so ask for that imaging if the denial says it was missing. Ask for the order, the notes, and any earlier studies the plan says it did not receive. How to request the record is in medical records and the claim file.

A private plan that is not Medicare Advantage uses its own imaging policy. Ask for that policy and for the criterion it says was missing. Do not treat NCD 220.6.17 as that plan's rule unless the plan adopted it. Do not treat another insurer's policy, or a policy for a different cancer, as the rule for this scan.

References: CMS NCD 220.6.17: FDG PET for oncologic conditions · HealthCare.gov: Preauthorization

How do I appeal a PET scan denial?

Use the deadline on the notice. For many non-grandfathered plans, 29 CFR 2560.503-1 gives a group health plan at least 180 days after you receive the denial to appeal, and 45 CFR 147.136 applies that standard to non-grandfathered group and individual coverage. HealthCare.gov says to file within 180 days of receiving the notice, and to request an external review in writing within 4 months if the internal appeal is denied and the dispute is a medical judgment, including medical necessity. If the notice gives you more time, follow the notice. The shared imaging appeal steps are in a CT scan denial and how to appeal a health insurance denial.

For Original Medicare, 42 CFR 405.942 says a redetermination must be filed within 120 calendar days after you receive the notice. Receipt is presumed five calendar days after the date on the notice unless there is evidence otherwise. The steps are in how to appeal an Original Medicare denial. Send the ordering physician's response to the criterion the notice named. A peer-to-peer call may not be the appeal. Ask whether it preserves the deadline. Nothing on this page says Medicare or the plan must approve the scan.

References: 29 CFR 2560.503-1: Claims procedure, including the 180-day appeal period · 45 CFR 147.136: Internal claims, appeals, and external review · HealthCare.gov: Internal appeals · HealthCare.gov: External review · 42 CFR 405.942: Original Medicare redetermination filing deadline · Medicare.gov: Appeals in Original Medicare

What this page cannot promise

This is general information, not medical or legal advice. A private plan can apply its own imaging policy. Medicare can deny an initial use the NCD marks non-covered, and a contractor can deny a fourth or later subsequent FDG PET. A scan with a different tracer follows a different section. An appeal can leave the denial in place. Nothing on this page promises that the scan will be covered or that a bill will be canceled.

Sources and further help

These sources provide general guidance. For a deadline or requirement that applies to you, follow your plan’s notice or the appropriate program’s current instructions.

Insurer websites may ask you to select your state or sign in. If a page will not open, use the member services number on your insurance card and ask for the current appeal instructions for your plan.

Report a broken link or suggest a correction.

← Explore all 141 guides